Related references
Note: Only part of the references are listed.Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions
John H. Sampson et al.
NEURO-ONCOLOGY (2007)
Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to Pseudomonas exotoxin
Gregory J. A. Murad et al.
CLINICAL CANCER RESEARCH (2006)
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents - Technical note
MT Krauze et al.
JOURNAL OF NEUROSURGERY (2005)
Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain
S Love et al.
NATURE MEDICINE (2005)
Safety and feasibility of convection-enhanced delivery of cotara for the treatment of malignant glioma: Initial experience in 51 patients
SJ Patel et al.
NEUROSURGERY (2005)
Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study
NK Patel et al.
ANNALS OF NEUROLOGY (2005)
Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma
IF Parney et al.
JOURNAL OF NEUROSURGERY (2005)
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study
JH Sampson et al.
NEURO-ONCOLOGY (2005)
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors
JH Sampson et al.
JOURNAL OF NEURO-ONCOLOGY (2003)
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease
SS Gill et al.
NATURE MEDICINE (2003)
Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin
JF Hamilton et al.
EXPERIMENTAL NEUROLOGY (2001)
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
E Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase I trial of recombinant immunotoxin anti-Tac(Fv)PE38 (LMB-2) in patients with hematologic malignancies
RJ Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias
AE Frankel et al.
LEUKEMIA (2000)
Share Paper
